Neutralizing antibodies in survivors of Sin Nombre and Andes hantavirus infection

Emerging Infectious Diseases

Volumn 12, Issue 1, 2006, Pages 166-168

  Valdivieso, Francisca ^a   Vial, Pablo ^a   Ferres, Marcela ^b   Ye, Chunyan ^c   Goade, Diane ^c   Cuiza, Analia ^a   Hjelle, Brian ^c,d,e  

^a UNIVERSIDAD DEL DESARROLLO   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d TriCore Reference Laboratory   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANIMAL CELL; ARTICLE; CHILE; CONTROLLED STUDY; HUMAN; NONHUMAN; RHESUS MONKEY; SIN NOMBRE VIRUS; UNITED STATES; VIRUS INFECTION; VIRUS TITRATION;

EID: 31344480378     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1201.050930     Document Type: Article

References (16)

1. Monroe MC, Morzunov SP, Johnson AM, Bowen MD, Artsob H, Yates T, et al. Genetic diversity and distribution of Peromyscus-borne hantaviruses in North America. Emerg Infect Dis. 1999;5:75-86.
2. Erratum in: Emerg Infect Dis. 1999;5:314.
3. Pini N. Hantavirus pulmonary syndrome in Latin America. Curr Opin Infect Dis. 2004;17:427-31.
4. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Ribavirin causes error catastrophe during Hantaan virus replication. J Virol. 2003;77:481-8.
5. Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis. 1991;164:1119-27.
6. Mertz GJ, Miedzinski L, Goade D, Pavia AT, Hjelle B, Hansbarger CO, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis. 2004;39:1307-13.
7. Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol. 2003;77:9894-905.
8. Bharadwaj M, Nofchissey R, Goade D, Koster F, Hjelle B. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis. 2000;182:43-8.
9. Ruggiero HA, Perez Isquierdo F, Milani HA, Barri A, Val A, Maglio F, et al. Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases. Presse Med. 1986;15:2239-42.
10. Ye C, Prescott J, Nofchissey R, Goade D, Hjelle B. Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome. Emerg Infect Dis. 2004;10:478-82.
11. Park K, Kim CS, Moon K-T. Protective effectiveness of hantavirus vaccine. Emerg Infect Dis. 2004;10:2218-20.
12. Hooper JW, Custer DM, Thompson E, Schmaljohn CS. DNA vaccination with the Hantaan virus M gene protects hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys. J Virol. 2001;75:8469-77.
13. Hooper JW, Larsen T, Custer DM, Schmaljohn CS. A lethal disease model for hantavirus pulmonary syndrome. Virology. 2001;289:6-14.
14. Hooper JW, Li D. Vaccines against hantaviruses. Curr Top Microbiol Immunol. 2001;256:171-91.
15. Hjelle B. Vaccines against hantaviruses. Expert Rev Vaccines. 2002;1:373-84.
16. Botten J, Mirowsky K, Kusewitt D, Bharadwaj M, Yee J, Ricci R, et al. Experimental infection model for Sin Nombre hantavirus in the deer mouse (Peromyscus maniculatus). Proc Natl Acad Sci U S A. 2000;97:10578-83.